GeneThera, Inc. (GTHR) Research

GeneThera, Inc. is a biotechnology firm dedicated to crafting advanced diagnostic tools and therapeutic solutions for diseases that can transfer from animals to humans (zoonotic diseases). The company's portfolio includes treatments for a variety of these conditions, such as COVID-19, and illnesses like paratuberculosis (Johne's disease), currently in its Stage III clinical phase, as well as mad cow and chronic wasting diseases, and common bacterial infections like E.coli and salmonella. Furthermore, GeneThera is developing a vaccine specifically targeting Mycobacterium avium subspecies paratuberculosis bacteria. Utilizing its innovative Molecular Robotic/AI Platform and a strategic therapeutic framework, the company strives to inhibit the spread of animal-borne diseases and improve control over zoonotic infectious agents. GeneThera, Inc. operates out of Westminster, Colorado.

Market snapshot

Symbol
GTHR
Price
$0.00
Day change
+0.00%
Market cap
$3.5K
P/E ratio
-0.00x
52-week range
0.000001-0.006
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Allied Healthcare Products, Inc. (AHPIQ)
  • Gene Biotherapeutics, Inc. (CRXM)
  • American CryoStem Corporation (CRYO)
  • DermTech, Inc. (DMTKQ)
  • EPIRUS Biopharmaceuticals, Inc. (EPRSQ)
  • ER Urgent Care Holdings, Inc. (ERUC)
  • Lescarden Inc. (LCAR)
  • Molecular Templates, Inc. (MTEM)

Recent insider activity

  • Kolesnikov Avel — trade (0 shares) on 2011-12-31
  • MILICI ANTONIO — P-Purchase (6400000 shares) on 2012-01-04
  • IRIZARRY TANNYA L — P-Purchase (2690000 shares) on 2011-12-31
  • MILICI ANTONIO — P-Purchase (6400008 shares) on 2012-01-04
  • McNece Elmer Roy Jr — P-Purchase (200000 shares) on 2008-02-25

Open GeneThera, Inc. (GTHR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.